Literature DB >> 17712183

Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia?

Eric C Eichenwald1, Ann R Stark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17712183      PMCID： PMC2675350          DOI： 10.1136/adc.2006.106583

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN： 1359-2998            Impact factor:   5.747


× No keyword cloud information.
  30 in total

1.  Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants.

Authors:  O Baud; L Foix-L'Helias; M Kaminski; F Audibert; P H Jarreau; E Papiernik; C Huon; J Lepercq; M Dehan; T Lacaze-Masmonteil
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

2.  Postnatal corticosteroids for preterm infants--do what we say, not what we do.

Authors:  Alan H Jobe
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

3.  Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease.

Authors:  Lex W Doyle; Henry L Halliday; Richard A Ehrenkranz; Peter G Davis; John C Sinclair
Journal:  Pediatrics       Date:  2005-03       Impact factor: 7.124

4.  Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age.

Authors:  T M O'Shea; J M Kothadia; K L Klinepeter; D J Goldstein; B G Jackson; R G Weaver; R G Dillard
Journal:  Pediatrics       Date:  1999-07       Impact factor: 7.124

5.  Randomized placebo-controlled trial of a 42-Day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants.

Authors:  J M Kothadia; T M O'Shea; D Roberts; S T Auringer; R G Weaver; R G Dillard
Journal:  Pediatrics       Date:  1999-07       Impact factor: 7.124

6.  Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants.

Authors:  Outi Peltoniemi; M Anneli Kari; Kirsti Heinonen; Timo Saarela; Kari Nikolajev; Sture Andersson; Raimo Voutilainen; Mikko Hallman
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

7.  Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial.

Authors:  Kristi L Watterberg; Jeffrey S Gerdes; Cynthia H Cole; Susan W Aucott; Elizabeth H Thilo; Mark C Mammel; Robert J Couser; Jeffery S Garland; Henry J Rozycki; Corinne L Leach; Conra Backstrom; Michele L Shaffer
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

Review 8.  Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants.

Authors:  H L Halliday; R A Ehrenkranz; L W Doyle
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 9.  Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants.

Authors:  H L Halliday; R A Ehrenkranz; L W Doyle
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity.

Authors:  Tsu F Yeh; Yuh J Lin; Hung C Lin; Chao C Huang; Wu S Hsieh; Chyi H Lin; Cheng H Tsai
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245
View more
  5 in total

1.  Risk factors affecting school readiness in premature infants with respiratory distress syndrome.

Authors:  Athena I Patrianakos-Hoobler; Michael E Msall; Jeremy D Marks; Dezheng Huo; Michael D Schreiber
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

Review 2.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

3.  Neonatal steroids induce a down-regulation of tenascin-C and elastin and cause a deceleration of the first phase and an acceleration of the second phase of lung alveolarization.

Authors:  Matthias Roth-Kleiner; Thomas M Berger; Sandrine Gremlich; Stefan A Tschanz; Sonja I Mund; Martin Post; Marco Stampanoni; Johannes C Schittny
Journal:  Histochem Cell Biol       Date:  2013-08-04       Impact factor: 4.304

4.  Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.

Authors:  Wes Onland; Martin Offringa; Filip Cools; Anne P De Jaegere; Karin Rademaker; Henry Blom; Eric Cavatorta; Anne Debeer; Peter H Dijk; Arno F van Heijst; Boris W Kramer; Andre A Kroon; Thilo Mohns; Henrica L van Straaten; Arjan B te Pas; Claire Theyskens; Mirjam M van Weissenbruch; Anton H van Kaam
Journal:  BMC Pediatr       Date:  2011-11-09       Impact factor: 2.125

5.  Pulmonary effects of neonatal hydrocortisone treatment in ventilator-dependent preterm infants.

Authors:  Sandra E A de Jong; Floris Groenendaal; Frank van Bel; Karin J Rademaker
Journal:  Int J Pediatr       Date:  2011-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.